Helen Torley - 09 Feb 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: PRESIDENT AND CEO, Director
Signature: /s/ James R. Oehler, Attorney-in-Fact
Issuer symbol: HALO
Transactions as of: 09 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2026, 20:56:32 UTC
Previous filing: 05 Feb 2026
Next filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Torley Helen	PRESIDENT AND CEO, Director	C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO	/s/ James R. Oehler, Attorney-in-Fact	11 Feb 2026	0001528185

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Award	$0	+53,847		$0.000000	53,847	09 Feb 2026	Common Stock	53,847	$80.48	Direct	F1
transaction	HALO	Restricted Stock Units	Award	$0	+50,013		$0.000000	50,013	09 Feb 2026	Common Stock	50,013	$0.000000	Direct	F2
transaction	HALO	Performance Stock Units	Award	$0	+19,807	+63%	$0.000000	51,171	09 Feb 2026	Common Stock	19,807	$0.000000	Direct	F3
transaction	HALO	Performance Stock Units	Award	$0	+24,985	+21%	$0.000000	144,400	09 Feb 2026	Common Stock	24,985	$0.000000	Direct	F4
transaction	HALO	Performance Stock Units	Award	$0	+92,714		$0.000000	92,714	09 Feb 2026	Common Stock	92,714	$0.000000	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vests one-fourth on such date and then 1/48th monthly thereafter.
F2	This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
F3	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
F4	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
F5	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.